Renaissance of waveform optimization? Class III antiarrhythmic drugs and the tail end of biphasic defibrillation shocks.
Schauerte
P N
PN
D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D004056:Differential Threshold / Q000187:drug effects; D004554:Electric Countershock; D006801:Humans; D013617:Tachycardia, Supraventricular / Q000628:therapy*; D017180:Tachycardia, Ventricular / Q000628:therapy*; D014693:Ventricular Fibrillation / Q000628:therapy*
D000889:Anti-Arrhythmia Agents